WuXi Biologics seals deal for first US production facility

SourceBiopharma Reporter
Date Published05/21/2020
Author NameBen Hargreaves
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name WuXi Biologics
Type of work Manufacturing
Reshoring category:Foreign Direct Investment
Total number of jobs (added or to be added):150
Year reshoring announced:2020
Year reshoring implemented or to be implemented:2022
Domestically, the work will be done:In-house
Capital investment ($):1.5
Country(ies) from which reshored:China
City reshored to:Worcester
State(s) reshored to:MA
If relevant, work nearshored to:-
Product(s) reshoredbiologics
What domestic positive factors made reshoring more attractive?Government Incentives
Government Incentive dollar amount:$17.5 million
Find Reshoring Articles